The 2012 J.P. Morgan Healthcare Conference includes several China-related events, which we describe; Harbin Pharma was given an official go-ahead to complete an $870 million corporate restructuring with its parent, Harbin Pharmaceutical Group; China Health Resource retained legal counsel to facilitate an international acquisition strategy; China announced new Foreign Direct Investment Guidelines that will encourage foreigners to invest in China biotechnology companies; and Yunnan Baiyao Group began operations in its new $396 million production facility. More details…. Stock Symbols: (SHA: 600664) (OTCBB: CHRI) (SHE: 000538) Share this with colleagues:   var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});